Streetbeat News

Stock Prices

PLRX

Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced two poster presentations, including a late-breaker, at the EASL International Liver Congress™ from June 5-8, 2024, focusing on its Bexotegrast program for fibrotic diseases.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 12:06 pm

CERO

CERo Therapeutics Holdings shares are trading higher following the announcement of the completion of toxicology studies for its lead compound, CER-1236.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 12:06 pm

CTKB

Cytek Biosciences has announced a $50 million stock repurchase program, indicating confidence in its financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 12:03 pm

VSCO

XRT

Victoria's Secret & Co. (NYSE:VSCO) reported a 3.4% Y/Y revenue decline for Q1 FY24, with total comparable sales down 5% Y/Y. Despite a challenging retail environment, the company managed to beat EPS estimates. The stock is down 2.92% premarket. Investors can also gain exposure through SPDR S&P Retail ETF (NYSE:XRT).

Portfolio Pulse from Lekha Gupta

June 06, 2024 | 12:03 pm

MDGL

Madrigal Pharmaceuticals announced new analyses from its Phase 3 MAESTRO-NASH trial of Resmetirom, to be presented at the EASL Congress in June 2024. The analyses show significant improvements in fibrotic features, liver stiffness, and health-related quality of life for patients treated with Resmetirom.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 12:02 pm

BE

Over the past three months, 9 analysts have shared their evaluations of Bloom Energy (NYSE:BE), with a mix of bullish, somewhat bullish, and indifferent ratings. The average 12-month price target has increased by 5.67% to $16.78. Analysts have adjusted their ratings and price targets based on recent developments, reflecting diverse outlooks on the company's performance.

Portfolio Pulse from Benzinga Insights

June 06, 2024 | 12:02 pm

HCP

JMP Securities has downgraded HashiCorp (NASDAQ:HCP) from Market Outperform to Market Perform, as per analyst Patrick Walravens.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 12:01 pm

SHOO

Analysts have mixed ratings for Steven Madden (NASDAQ:SHOO) over the past three months, with one bullish rating in the last 30 days. The average 12-month price target has increased to $45.5. Key analysts have maintained or raised their ratings, reflecting positive sentiment. Steven Madden has shown strong financial performance with notable revenue growth, net margin, ROE, and ROA, and maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

June 06, 2024 | 12:01 pm

FANG

Diamondback Energy (NASDAQ:FANG) has received mixed ratings from 19 analysts, with a majority being somewhat bullish. The average 12-month price target is $224.26, reflecting a 7.85% increase from the previous target. Analysts have adjusted their ratings and price targets based on recent company performance and market conditions.

Portfolio Pulse from Benzinga Insights

June 06, 2024 | 12:01 pm

UAL

Over the past three months, 11 analysts have evaluated United Airlines Holdings (NASDAQ:UAL), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 7.22% to $68.93. Recent analyst actions include several upgrades and new ratings, reflecting positive sentiment towards the company.

Portfolio Pulse from Benzinga Insights

June 06, 2024 | 12:00 pm